The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 and older, including death.

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

The risk for COVID-19-related hospitalization was not significantly different between vaccinated older adults with vs without age-restrictive access to nirmatrelvir-ritonavir.